Adverse Drug Reaction News Bulletins
ADR News Bulletin 2012 April (Volume 14 Number 1)
Audiences
Healthcare professional
Industry member
Product type
Therapeutic Products
1 April 2012
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Domperidone and risk of cardiac arrhythmia and sudden cardiac death
Good Manufacturing Practices (GMP) deficiencies at Ben Venue Laboratories Inc, USA
Early termination of aliskiren study due to adverse events
Analysis of Adverse Event (AE) Reports for Year 2011
Medication errors arising from brand name confusion between Pradax® (dabigatran etexilate) and Plavix® (clopidogrel hydrogen sulphate) in Canada
Phasing-out of serratiopeptidase-containing preparations as medicinal products
Updates on the exemptions for supply of Prescription-Only Medicine (POM) without prescription
Cessation on production and commercialisation of Duxaril® (almitrine and raubasine)
Risk of dose-dependent QT prolongation with citalopram
Click on the link below to download the issue in pdf:
ADR_News_Apr2012_Vol14_No1 [PDF, 851 KB]